title: Effects of Recombinant Human Growth Hormone for Osteoporosis: Systematic Review and Meta-Analysis.
abstract: Our objective was to evaluate the efficacy of recombinant human growth hormone (GH) on bone mineral density (BMD) in persons age 50 and older, with normal pituitary function, with or at risk for developing osteoporosis. We systematically reviewed randomized clinical trials (RCTs), searching six databases, and conducted meta-analyses to examine GH effects on BMD of the lumbar spine and femoral neck. Data for fracture incidence, bone metabolism biomarkers, and adverse events were also extracted and analysed. Thirteen RCTs met the eligibility criteria. Pooled effect sizes suggested no significant GH effect on BMD. Pooled effect sizes were largest, but nonsignificant, when compared to placebo. GH had a significant effect on several bone metabolism biomarkers. A significantly higher rate of adverse events was observed in the GH groups. Meta-analysis of RCTs suggests that GH treatment for persons with or at risk for developing osteoporosis results in very small, nonsignificant increases in BMD.
authors.affiliation: Wolf Orthopaedic Biomechanics Lab,Fowler Kennedy Sport Medicine Clinic,University of Western Ontario.
authors.forename: Hayden F
authors.initials: HF
authors.lastname: Atkinson
authors.affiliation: Wolf Orthopaedic Biomechanics Lab,Fowler Kennedy Sport Medicine Clinic,University of Western Ontario.
authors.forename: Rebecca F
authors.initials: RF
authors.lastname: Moyer
authors.affiliation: Faculty of Health Sciences,University of Western Ontario.
authors.forename: Daniel
authors.initials: D
authors.lastname: Yacoub
authors.affiliation: School of Occupational Therapy,Dalhousie University.
authors.forename: Dexter
authors.initials: D
authors.lastname: Coughlin
authors.affiliation: Wolf Orthopaedic Biomechanics Lab,Fowler Kennedy Sport Medicine Clinic,University of Western Ontario.
authors.forename: Trevor B
authors.initials: TB
authors.lastname: Birmingham
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D005260:Female; D005272:Femur Neck / Q000187:drug effects; D050723:Fractures, Bone / Q000517:prevention & control; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012306:Risk
chemical_list: D050071:Bone Density Conservation Agents; D011994:Recombinant Proteins; D019382:Human Growth Hormone
keywords: aging; bone mineral density; densité minérale osseuse; examen systématique; growth hormone; hormone de croissance; meta-analysis; méta-analyse; osteoporosis; ostéoporose; systematic review; vieillissement